Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells - PubMed (original) (raw)
Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells
Takuichiro Hide et al. Stem Cells. 2011 Apr.
Abstract
Recent findings have demonstrated that malignant tumors, including glioblastoma multiforme (GBM), contain cancer-initiating cells (CICs; also known as cancer stem cells), which self-renew and are malignant. However, it remains controversial whether such CICs arise from tissue-specific stem cells, committed precursor cells, or differentiated cells. Here, we sought to examine the origin of the CICs in GBM. We first showed that the overexpression of oncogenic HRas(L61) transformed p53-deficient oligodendrocyte precursor cells (OPCs) and neural stem cells (NSCs) into glioma-initiating cell (GIC)-like cells in mice. When as few as 10 of these GIC-like cells were transplanted in vivo, they formed a transplantable GBM with features of human GBM, suggesting that these GIC-like cells were enriched in CICs. DNA microarray analysis showed that widespread genetic reprogramming occurred during the OPCs' transformation: they largely lost their OPC characteristics and acquired NSC ones, including the expression of prominin1, hmga2, ptgs2, and epiregulin. In addition, the combination of a Ptgs2 inhibitor and an epidermal growth factor receptor (EGFR)-signaling inhibitor prevented the tumorigenesis of transformed OPCs and human GICs (hGICs) obtained from anaplastic oligodendroglioma, but not of transformed NSCs or hGICs obtained from GBM. Together, these findings suggest that GBM can arise from either OPCs or NSCs and that the therapeutic targets for GBM might be different, depending on each GIC's cell-of-origin.
Copyright © 2011 AlphaMed Press.
Similar articles
- Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation.
Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T. Hide T, et al. Cancer Res. 2009 Oct 15;69(20):7953-9. doi: 10.1158/0008-5472.CAN-09-2006. Epub 2009 Oct 6. Cancer Res. 2009. PMID: 19808959 - Mouse induced glioma-initiating cell models and therapeutic targets.
Kondo T. Kondo T. Anticancer Agents Med Chem. 2010 Jul;10(6):471-80. doi: 10.2174/1871520611009060471. Anticancer Agents Med Chem. 2010. PMID: 20879984 - Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo.
Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, Grande L, Casafont I, Segura V, Robles EF, Suarez D, Garcia LF, Martinez-Climent JA, Fernandez-Luna JL. Nogueira L, et al. Oncogene. 2011 Aug 11;30(32):3537-48. doi: 10.1038/onc.2011.74. Epub 2011 Mar 21. Oncogene. 2011. PMID: 21423202 - From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage.
Noble M, Gutowski N, Bevan K, Engel U, Linskey M, Urenjak J, Bhakoo K, Williams S. Noble M, et al. Glia. 1995 Nov;15(3):222-30. doi: 10.1002/glia.440150304. Glia. 1995. PMID: 8586459 Review. - EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, Drouin R, Klonisch T. Gadji M, et al. Eur J Pharmacol. 2009 Dec 25;625(1-3):23-30. doi: 10.1016/j.ejphar.2009.10.010. Epub 2009 Oct 18. Eur J Pharmacol. 2009. PMID: 19836372 Review.
Cited by
- Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma.
Wang Q, Zhang Y, Zhang B, Fu Y, Zhao X, Zhang J, Zuo K, Xing Y, Jiang S, Qin Z, Li E, Guo H, Liu Z, Yang J. Wang Q, et al. Nat Commun. 2022 Jan 10;13(1):31. doi: 10.1038/s41467-021-27660-3. Nat Commun. 2022. PMID: 35013217 Free PMC article. - Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.
Paul I, Bhattacharya S, Chatterjee A, Ghosh MK. Paul I, et al. Genes Cancer. 2013 Nov;4(11-12):427-46. doi: 10.1177/1947601913503341. Genes Cancer. 2013. PMID: 24386505 Free PMC article. Review. - On the origin of glioma.
Jiang Y, Uhrbom L. Jiang Y, et al. Ups J Med Sci. 2012 May;117(2):113-21. doi: 10.3109/03009734.2012.658976. Epub 2012 Feb 21. Ups J Med Sci. 2012. PMID: 22348397 Free PMC article. - Ribosomes and Ribosomal Proteins Promote Plasticity and Stemness Induction in Glioma Cells via Reprogramming.
Hide T, Shibahara I, Inukai M, Shigeeda R, Kumabe T. Hide T, et al. Cells. 2022 Jul 7;11(14):2142. doi: 10.3390/cells11142142. Cells. 2022. PMID: 35883585 Free PMC article. Review. - Utility of network integrity methods in therapeutic target identification.
Peng Q, Schork NJ. Peng Q, et al. Front Genet. 2014 Feb 3;5:12. doi: 10.3389/fgene.2014.00012. eCollection 2014. Front Genet. 2014. PMID: 24550933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous